Content by Keyword: Drug Therapy

Basic report
bar chart: comparison of prescription drug

A National Comparison of Prescription Drug Expenditures by Medicare Beneficiaries Living in the Community and Long-Term Care Facility Settings

U.S. Department of Health and Human Services A National Comparison of Prescription Drug Expenditures by Medicare Beneficiaries Living in the Community and Long-Term Care Facility Settings Linda Simoni-Wastila, PhD, Thomas Shaffer, MHS and Bruce Stuart, PhD University of Maryland, Baltimore, Peter Lamy Center on Drug Therapy
  • pdnatcom.pdf
    export-csvPDF
Basic report
bar chart: total LTCF prescription drug spending

National Estimates of Prescription Drug Utilization and Expenditures in Long-Term Care Facilities

U.S. Department of Health and Human Services National Estimates of Prescription Drug Utilization and Expenditures in Long-Term Care Facilities Linda Simoni-Wastila, PhD, Thomas Shaffer, MHS and Bruce Stuart, PhD University of Maryland, Baltimore, Peter Lamy Center on Drug Therapy and Aging October 25, 2006 PDF Version (2
  • pdnatest.pdf
    export-csvPDF
Basic report
Bar Chart: comparison of prescription drug

Prescription Drug Spending by Medicare Beneficiaries in Institutional and Residential Settings, 1998-2001

U.S. Department of Health and Human Services Prescription Drug Spending by Medicare Beneficiaries in Institutional and Residential Settings, 1998-2001 Linda Simoni-Wastila, PhD, Bruce Stuart, PhD, and Thomas Shaffer, MS University of Maryland, Baltimore, Peter Lamy Center on Drug Therapy and Aging June 2007 PDF Version (
  • pdspend.pdf
    export-csvPDF
Report
Examination of Clinical Trial Costs and Barriers

Examination of Clinical Trial Costs and Barriers for Drug Development

Pharmaceutical companies conduct clinical trials for many reasons. The most obvious goal of clinical trials is to demonstrate safety and efficacy to gain Food and Drug Administration (FDA) approval. FDA provides guidance to developers about what constitutes acceptable clinical trials and appropriate outcomes. Improving the drug development process
  • rpt_erg.pdf
    export-csvPDF
Report
Analytical Framework for Examining the Value of

Analytical Framework for Examining the Value of Antibacterial Products

Antibacterial resistance is a growing global problem.  At least 2 million people in the U.S. acquire serious infections with bacteria that are resistant to one or more of antibacterial drugs designed to treat it.  Despite the potential of new antibacterial products to reduce the social burden associated with resistant infections, development of
  • rpt_antibacterials.pdf
    export-csvPDF
Report
Diabetes: A National Plan for Action

Diabetes: A National Plan for Action

Currently, more than 18 million Americans have diabetes and are at risk for related complications like heart disease, stroke, blindness, amputations, and kidney disease. This document provides up-to-date and accurate prevention, detection, and treatment information, and includes simple action steps for individuals, families, health practitioners,
  • NDAP04.pdf
    export-csvPDF
Report
Performance Improvement 2008

Performance Improvement 2008

This Performance Improvement series of reports takes its name from the primary goal of carrying out evaluations – to improve the performance of programs meant to serve the greatest needs of the community. Performance Improvement 2008, the latest of these reports, makes available the most recently completed evaluations of the Department of Health
  • PerformanceImprovement2008.pdf
    export-csvPDF
Report
Performance Improvement 1999

Performance Improvement 1999

Performance Improvement 1999: Evaluation Activities of the U.S. Department of Health and Human Services is the fifth annual report to Congress summarizing previous fiscal year evaluation efforts. The purpose of this report is to provide Congress with evaluative information on the Department's programs, policies, activities, and strategies. It cont
Report
Performance Improvement 2005

Performance Improvement 2005

Performance Improvement 2005: Evaluation Activities of the U.S. Department of Health and Human Services, complies with Section 241(b) of the Public Health Service Act, as amended by the Preventive Health Amendments of 1993. This is the 11th annual report to Congress. Performance Improvement 2005 provides results-oriented findings regarding the Depa
  • pi_2005.pdf
    export-csvPDF

Pages